Granulocyte-macrophage colony-stimulating factor - Cangene

Alternative Names: GM-CSF Cangene; Granulocyte-macrophage colony-stimulating factor; Leucotropin; rhGM-CSF

Latest Information Update: 02 Oct 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cangene Corporation
Developer Apotex; Cangene Corporation; Emergent BioSolutions
Class Adjuvants; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
Mechanism of Action Granulocyte macrophage colony stimulating factor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
14 Mar 2007 Leucotropin^® is still in active development
09 Oct 2003 Preregistration for Neutropenia in Canada (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com